CLARIVATE PLC 8-K

What Happened
Clarivate Plc announced on July 6, 2026 that it has entered into an agreement to sell its Life Sciences & Healthcare business to an affiliate of Altaris, LLC. The purchase agreement contains customary representations, warranties and covenants. Clarivate furnished a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) with the Form 8-K and will deliver an investor presentation on a related conference call; those materials are posted on the company’s investor relations website.

Key Details

• Date announced: July 6, 2026.
• Buyer: an affiliate of Altaris, LLC (private equity affiliate).
• Purchase agreement: includes customary representations, warranties and covenants (no purchase price or closing date disclosed in the 8-K).
• Investor materials: press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) posted to Clarivate’s IR site; an investor presentation will be delivered on the conference call.

Why It Matters
This is a material divestiture for Clarivate that could affect the company’s portfolio, capital allocation and future financial results once transaction terms, proceeds and timing are disclosed. The 8-K includes forward-looking statements about potential uses of proceeds, cost savings, guidance and other impacts; investors should review the posted press release and supplemental presentation for more details and monitor future SEC filings for definitive transaction terms and closing conditions.